相关实验视频

Updated: Jul 5, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

雷拉特利马布:一种针对黑色素瘤治疗中的免疫检查点LAG-3的新药

Jingjing Su¹, Yiting Fu¹, Zitong Cui¹

¹Key Laboratory of Molecular Pharmacology and Translational Medicine and Department of Pharmacology, College of Pharmacy, Weifang Medical University, Weifang, China.

Frontiers in pharmacology

|January 25, 2024

概括

雷拉利马布是第一个淋巴细胞激活基因-3 (LAG-3) 抑制剂,在治疗黑色素瘤方面表现有前途. 它与尼沃卢马布 (Opdualag) 的组合已获得FDA批准,用于晚期黑色素瘤.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

雷拉利马布是一种新型的人类免疫球蛋白G4单克隆抗体.
它作为第一类的淋巴细胞激活基因-3 (LAG-3) 抑制剂.
它代表了第三类免疫检查点抑制剂,仅次于PD-1和CTLA-4.

研究的目的:

详细描述relatlimab的作用机制.
审查调查relatlimab的临床试验.
为提供当前用于黑色素瘤治疗的免疫检查点抑制剂的概述.

主要方法:

审查科学文献和临床试验数据.
对relatlimab与LAG-3受体的结合的分析.
检查对T细胞活动和瘤细胞死亡的影响.

主要成果:

雷拉利马布阻断LAG-3相互作用,减少免疫抑制并促进T细胞增殖.
固定剂量的relatlimab和nivolumab (Opdualag) 组合在2022年3月18日获得FDA批准.
在12岁及以上的患者中,Opdualag适用于不可切除或转移性黑色素瘤.

结论:

雷拉利马布通过准LAG-3通路,为黑色素瘤提供了一种新的治疗策略.
组合疗法代表了黑色素瘤治疗免疫瘤学的重大进展.
对LAG-3抑制的进一步研究可能会为各种癌症提供额外的治疗选择.

关键词:

这是一种LAG-3抑制剂.免疫检查点是一个检查点.发生转移的黑色素瘤.这就是尼沃卢马布 (nivolumab).有关可能的关系.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...